Our guest: David W. Moskowitz, MD
- Chairman, Chief Executive Officer, and Chief Medical Officer, and Founder of GenoMed, Inc. (GenoMed.com) Dr. Moskowitz majored in Chemistry (summa cum laude) at Harvard College, Biochemistry (first class honours) at Merton College, Oxford, and received an MD (cum laude) from the Harvard-MIT Division in Health Sciences and Technology (Harvard Medical School). He trained for 7 years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. Since 1994, Dr. Moskowitz has experienced first hand the clinical effectiveness of knowing a disease-associated gene (the angiotensin converting enzyme, or ACE, gene). Dr. Moskowitz is a pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes.
Arlene Mullin — advocate, 20 years experience guiding patients and their families through all aspects of End Stage Renal Disease treatments. Mullin has served patients in a majority of states, engaging both Medicare and state health authorities towards resolution of quality care issues at clinics. Comprehensive knowledge of care issues on clinic level. She was instrumental in getting the hearings on aging before the U.S. Senate in 2000 where she testified on patient care issue within the dialysis industry.
Dialysis Advocates is grateful for the opportunity to get this important message out for all Dialysis Patients.